New Drug Combats Late-stage Prostate Cancer by Angela Mohan on July 12, 2021 at 11:18 AM
New treatment combats late stage prostate cancer by delivering beta radiation directly to tumour cells. It is well tolerated by patients and keeps them alive for longer compared to standard care, as per the phase 3 trial findings.
New approach, targets a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
International team of researchers set out to see whether Lu-PSMA-617 was more effective than standard care and recruited 831 patients with metastatic castration-resistant prostate cancer between June 2018 and October 2019. Patients were randomized to receive the treatment plus standard care or standard care alone.
Enhancing Effectiveness of drugs Against Prostate Cancer by Angela Mohan on April 21, 2021 at 5:04 PM
Advanced Functional Materials.
Researchers also investigated whether this system helps more drugs across the vessel wall and deeply into the tumor tissue.
Although nucleotide drugs offer advantages in treating tumors and other diseases, they often suffer from a poor efficiency of crossing the blood vessels and entering the tumor tissue, where their targets reside. This problem greatly limits their clinical applicability and efficacy. Our system demonstrates a good ability to deliver more ASOs into both primary tumor tissue and bone metastases which is the primary site for prostate cancer metastasis, said Pang, an assistant professor in the College of Pharmacy and a member of the Masonic Cancer Center.